hit
discoveri
first
step
drugdiscoveri
pathway
chemic
start
point
identifi
usual
involv
screen
collect
compound
molecular
target
typic
enzym
targetbas
screen
whole
organ
cellbas
phenotyp
screen
altern
approach
hit
discoveri
includ
structurebas
drug
discoveri
repurpos
drug
diseas
area
silico
method
next
hit
expans
perform
verifi
hit
genuin
whether
scope
work
chemotyp
compound
refin
cyclic
process
hit
lead
phase
signific
activ
typic
anim
model
infect
subsequ
biolog
activ
pharmacokinet
safeti
profil
seri
optim
balanc
lead
optim
phase
candid
select
mark
import
mileston
drugdiscoveri
pathway
involv
select
singl
compound
progress
process
regulatori
toxicolog
scaleup
carri
enabl
initi
human
studi
human
clinic
trial
compound
first
test
healthi
volunt
measur
pharmacokinet
safeti
phase
follow
studi
establish
efficaci
phase
ii
largescal
efficaci
safeti
studi
phase
iii
drugdiscoveri
pathway
guid
target
product
profil
tpp
describ
desir
featur
requir
final
drug
product
durat
treatment
whether
treatment
oral
parenter
cost
treatment
accept
safeti
margin
among
tpp
defin
chaga
dengu
absent
mani
diseas
hamper
drugdiscoveri
process
tpp
use
develop
compound
progress
criteria
inform
requir
diseasespecif
profil
compound
everi
step
along
drugdiscoveri
process
includ
exampl
activ
particular
assay
pharmacokinet
profil
select
medicin
malaria
ventur
mmv
sever
exampl
compound
progress
criteria
http
wwwmmvorgresearchdevelopmentinformationscientist
wellvalid
molecular
drug
target
tropic
diseas
part
owe
lack
understand
detail
biolog
mani
pathogen
exampl
function
mani
protein
unknown
infer
organ
therefor
key
challeng
select
suitabl
molecular
target
limit
risk
subsequ
criteria
use
help
select
appropri
target
includ
essenti
druggabl
assay
opportun
select
host
even
target
compli
criteria
inhibitor
frequent
fail
demonstr
cellbas
activ
owe
poor
permeabl
inabl
compet
high
substrat
concentr
cell
compound
inhibit
target
suffici
kill
pathogen
defici
genet
tool
mani
diseaserelev
organ
key
reason
littl
essenti
data
avail
howev
new
technolog
includ
offer
prospect
markedli
increas
number
valid
target
avail
near
futur
largescal
cellbas
phenotyp
screen
current
popular
approach
identifi
new
chemic
start
point
requir
prior
knowledg
molecular
develop
assay
suffici
throughput
allow
screen
compound
librari
maintain
relev
diseas
pathophysiolog
challeng
help
reduc
attrit
use
vivo
model
ultim
clinic
assay
increas
relev
usual
becom
complex
requir
resourc
term
specialist
equip
well
staff
develop
run
assay
challeng
may
includ
lack
robust
vitro
cultur
system
exampl
cryptosporidium
inher
safeti
challeng
handl
diseasecaus
agent
bulk
lack
standard
differ
laboratori
work
organ
use
laboratori
strain
cell
line
rather
recent
clinic
isol
primari
exist
anim
model
tropic
diseas
infect
often
poorli
repres
human
diseas
exampl
onchocerciasi
river
blind
caus
worm
onchocerca
volvulu
infect
primat
consequ
relat
differ
worm
speci
use
mice
cattl
model
plasmodium
falciparum
pathogen
caus
sever
form
human
malaria
infect
rodent
normal
howev
scid
mous
model
develop
infect
p
work
also
ongo
develop
mous
model
human
malaria
caus
plasmodium
mous
model
tuberculosi
replic
human
diseas
well
form
granuloma
typic
human
diseas
encouragingli
progress
made
develop
anim
model
close
replic
human
recent
human
clinic
trial
azol
inhibit
enzym
treatment
chaga
diseas
success
mous
model
develop
distinguish
benznidazol
known
clinic
efficaci
azol
posaconazol
better
differenti
preclin
stage
improv
success
rate
clinic
trial
dormant
infect
complic
aetiolog
diseas
malaria
p
vivax
plasmodium
oval
remain
dormant
hypnozoit
hepatocyt
human
host
week
year
potenti
caus
latent
tuberculosi
clinic
symptom
absent
risk
progress
clinic
diseas
estim
affect
third
global
dormanc
recent
identifi
trypanosoma
quiescent
dormant
pathogen
reduc
metabol
compar
activ
divid
pathogen
may
therefor
less
suscept
drug
develop
assay
form
pathogen
problemat
effect
treat
elimin
diseas
new
drug
need
effect
tackl
reservoir
dormant
quiescent
infect
essenti
compound
use
treatment
dose
appropri
usual
oral
reach
part
bodi
pathogen
locat
physicochem
properti
molecul
molecular
weight
solubl
lipophil
charg
number
hydrogen
bond
donor
acceptor
fundament
achiev
case
penetr
pathogen
problemat
exampl
gramneg
bacteria
surround
outer
membran
drug
molecul
penetr
protein
form
channel
membran
call
porin
tend
select
hydrophil
molecul
drug
travers
cell
membran
lipid
bilay
requir
compound
degre
lipophil
therefor
penetr
cytoplasm
compound
requir
defin
chemic
properti
like
polar
charg
typic
penetr
cytoplasm
drug
risk
pump
bacteria
efflux
transport
pathogen
cruzi
chlamydia
trachomati
mycobacterium
tuberculosi
virus
spend
major
life
cycl
insid
human
host
cell
imped
drug
access
pathogen
local
extrem
intracellular
environ
acid
organel
exampl
leishmania
spp
salmonella
spp
necrot
granuloma
exampl
tuberculosi
latter
case
major
challeng
design
drug
penetr
nonvascular
lipidrich
caseum
access
infect
local
site
protect
barrier
central
nervou
system
exampl
hat
cryptococcu
neoforman
taenia
solium
enceph
meningitiscaus
virus
bacteria
eye
exampl
c
trachomati
reach
site
drug
need
pass
endotheli
cell
without
pump
back
blood
natur
diseas
mean
cost
treatment
must
low
malaria
aim
produc
treatment
cost
less
us
impli
short
cheap
chemic
synthesi
preclud
complex
formul
counter
issu
poor
solubl
owe
lack
temperaturecontrol
suppli
chain
mani
region
compound
stabl
long
period
time
high
temperatur
high
humid
requir
final
patient
complianc
also
challeng
often
compound
minim
medic
support
consequ
essenti
minim
number
dose
complex
dose
regimen
exampl
mmv
aim
singledos
treatment
bloodstream
drug
resist
consider
problem
treatment
infecti
diseas
particular
viral
bacteri
apicomplexan
poor
manag
treatment
acceler
occurr
resist
public
current
exampl
antibacteri
drug
resist
human
antibiot
sometim
taken
requir
given
subtherapeut
dose
potenti
increas
proport
resist
bacteria
within
popul
problem
aggrav
larg
amount
antibiot
environ
owe
indiscrimin
use
agricultur
aquacultur
combin
therapi
adopt
mani
diseas
attempt
slow
develop
drug
resist
particularli
success
treatment
hivaid
resist
rate
singl
except
high
combin
treatment
also
prove
effect
tuberculosi
malaria
worryingli
case
malaria
resist
artemisinin
combin
therapi
princip
form
develop
southeast
asia
therefor
need
drug
novel
mode
action
deliv
new
combin
therapi
clinic
resist
compon
million
case
year
human
econom
cost
malaria
extrem
africa
bear
disproportion
high
share
burden
death
year
multipl
new
type
antimalari
drug
need
overcom
resist
give
singledos
treatment
prevent
relaps
p
vivax
infect
block
transmiss
act
chemoprev
malaria
drugdiscoveri
portfolio
markedli
improv
past
start
point
major
compound
current
develop
identifi
phenotyp
screen
collabor
mmv
mani
case
target
deconvolut
subsequ
led
identif
molecular
target
number
novel
compound
clinic
trial
support
collabor
mmv
fig
follow
deriv
phenotyp
screen
phase
ii
trial
spiroindolon
imidazolopiperazin
combin
trial
lumefantrin
synthet
trioxolan
artefenomel
combin
ferroquin
mode
action
determin
p
falciparum
pf
wherea
mode
action
remain
uncertain
link
cyclic
amin
resist
locu
pfcarl
probabl
act
format
carbon
radic
wherea
ferroquin
act
prevent
haem
detoxif
phase
trial
dihydroisoquinolin
anoth
activ
translat
elong
factor
two
compound
deriv
targetbas
project
also
clinic
trial
dihydroorot
dehydrogenas
inhibitor
phase
ii
trial
dihydrofol
reductas
inhibitor
phase
trial
envisag
increas
targetbas
drug
discoveri
modeofact
studi
reveal
chemic
valid
target
mani
recent
identifi
phenotyp
hit
systemat
effort
tri
identifi
mode
action
phenotyp
new
type
phenotyp
screen
develop
target
lifecycl
stage
addit
asexu
blood
clinic
develop
malaria
acceler
thank
develop
human
challeng
model
healthi
volunt
infect
treatabl
malaria
obtain
earli
indic
drug
cryptosporidiosi
major
caus
diarrhoea
children
tropic
countri
box
nitazoxanid
current
treatment
diseas
variabl
efficaci
immunocompet
patient
effect
immunocomprom
urgent
need
new
drug
treat
children
month
age
especi
malnourish
immunocomprom
suffer
chronic
diarrhoea
recent
advanc
cryptosporidiosi
discoveri
pipelin
seri
bump
kinas
inhibitor
cryptosporidium
parvum
calciumdepend
kinas
develop
exampl
promisingli
recent
advanc
c
parvum
highcont
imag
infect
assay
human
intestin
epitheli
cell
made
phenotyp
screen
medium
larges
compound
librari
possibl
screen
compound
activ
malaria
led
identif
preclin
candid
inhibitor
cryptosporidium
phosphatidylinositol
clofazimin
approv
drug
treatment
leprosi
identifi
screen
bioactiv
enter
clinic
trial
cryptosporidiosi
area
recent
review
mortal
rate
hat
also
known
sleep
sick
decreas
substanti
recent
howev
still
consider
diseas
burden
central
africa
advent
nect
combin
therapi
mark
import
step
treatment
stage
two
brucei
gambiens
hat
reduc
durat
treatment
well
decreas
advers
nevertheless
treatment
still
problemat
two
subspeci
caus
diseas
brucei
gambiens
brucei
rhodesiens
two
stage
acut
central
nervou
system
requir
differ
requir
stage
patient
treatment
also
limit
uptak
involv
pain
technic
challeng
lumbar
ongo
develop
two
new
drug
potenti
transform
clinic
manag
first
drug
fexinidazol
nitroaromat
compound
develop
broadspectrum
antibiot
recent
found
suitabl
profil
clinic
develop
drug
neglect
diseas
initi
dndi
complet
phase
iii
clinic
trial
report
noninferior
nect
stage
diseas
tenday
oral
second
oxaborol
compound
acoziborol
current
undergo
pivot
phase
iiiii
potenti
provid
singledos
oral
treatment
form
hat
less
progress
made
leishmaniasi
chaga
diseas
current
treatment
particularli
liposom
amphotericinb
given
intraven
togeth
measur
vector
control
effect
surveil
led
progress
toward
elimin
control
viscer
leishmaniasi
vl
indian
subcontin
howev
current
drug
less
effect
unsuit
area
world
new
oral
drug
urgent
need
treat
vl
region
provid
improv
treatment
option
indian
subcontin
furthermor
coinfect
also
current
poorli
treat
sever
potenti
oral
treatment
identifi
phenotyp
screen
preclin
develop
includ
oxaborol
discoveri
pankinetoplastid
proteasom
fig
offer
potenti
develop
new
drug
leishmaniasi
chaga
diseas
hat
major
preclin
work
leishmaniasi
focus
vl
deadli
form
diseas
rather
cutan
leishmaniasi
cl
new
oral
therapi
cl
urgent
need
well
research
chaga
diseas
suffer
setback
recent
consequ
clinic
failur
inhibitor
posaconazol
current
treatment
develop
challeng
diseas
virus
hiv
hepat
c
viru
hcv
dengu
rabi
larg
global
impact
fig
result
million
death
effect
treatment
hiv
hcv
virus
includ
flavivirus
arenavirus
coronavirus
filovirus
still
pose
consider
threat
tropic
countri
other
pose
particular
risk
global
pandem
exemplifi
recent
outbreak
middl
east
respiratori
syndrom
mer
sinc
futur
epidem
almost
inevit
could
trigger
member
famili
drugdiscoveri
effort
rightli
focu
broadact
diseas
receiv
rel
littl
attent
term
smallmolecul
drug
discoveri
howev
targetbas
cellbas
hit
discoveri
approach
yield
new
compound
interest
date
none
develop
similar
degre
hcv
hiv
advanc
compound
favipiravir
remdesivir
galidesivir
target
viral
polymeras
fig
favipiravir
test
human
ebola
viru
epidem
although
condit
complic
studi
conclud
investig
shown
activ
rhesu
monkey
model
also
use
human
ebola
outbreak
current
undergo
phase
ii
clinic
trial
west
africa
favipiravir
consid
use
ebola
viru
outbreak
democrat
republ
demonstr
complet
protect
marburg
viru
nonhuman
primat
ebola
rodent
model
administ
within
h
infect
compound
also
show
broad
activ
virus
includ
arenavirus
current
clinic
develop
inhibitor
target
viral
proteas
far
advanc
except
hiv
hcv
howev
also
show
promis
broadspectrum
antivir
potenti
target
host
pathway
also
although
new
smallmolecul
antivir
discov
urgent
need
translat
treatment
clinic
alongsid
ongo
vaccin
develop
tuberculosi
continu
major
problem
across
world
malaria
combin
treatment
use
tuberculosi
combat
resist
circumv
issu
tuberculosi
resid
multipl
environ
metabol
state
need
combin
therapi
complic
progress
new
compound
clinic
trial
http
wwwtballianceorgportfolio
recent
two
new
drug
bedaquilin
delamanid
condit
approv
treatment
specif
level
drugresist
tuberculosi
basi
phase
iib
trial
current
undergo
phase
iii
bedaquilin
target
atp
activ
latent
form
delamanid
nitro
heterocycl
precis
mode
action
determin
probabl
prodrug
requir
activ
insid
bacterium
implic
inhibit
mycol
acid
biosynthesi
critic
structur
cell
wall
number
compound
current
develop
treatment
tuberculosi
target
protein
synthesi
respiratori
chain
cell
envelop
http
wwwtballianceorgportfolio
http
wwwnewtbdrugsorgpipelineclin
sever
differ
step
protein
synthesi
studi
linezolid
demonstr
activ
drugresist
tuberculosi
mark
effect
patient
extens
drugresist
member
oxazolidinon
class
molecul
target
ribosom
subunit
howev
advers
effect
associ
extend
treatment
period
linezolid
requir
multidrugresist
tuberculosi
link
mitochrondri
oxazolidinon
sutezolid
delpazolid
undergo
clinic
avoid
mitochondri
toxic
allow
develop
oxazolidinon
analogu
higher
toler
oxaborol
inhibitor
leucyltrna
synthetas
enzym
involv
protein
synthesi
progress
clinic
form
coval
adduct
acceptor
nucleotid
trna
boron
bind
group
complex
form
edit
site
inactiv
enzym
enter
clinic
trial
target
respiratori
inhibit
cytochrom
pathway
target
bedaquilin
although
act
differ
step
hit
multipl
point
pathway
appear
enhanc
kill
target
cell
wall
biosynthesi
also
reinvestig
treatment
tuberculosi
carbapenem
appear
potenti
class
compound
protein
target
much
weaker
substrat
tuberculosi
sever
enzym
involv
cell
envelop
biosynthesi
promiscu
target
includ
former
involv
biosynthesi
arabinogalactan
polysaccharid
critic
cell
wall
biosynthesi
benzothiazon
found
coval
inhibitor
enzym
one
compound
preclin
develop
anoth
undergo
clinic
evalu
http
wwwnewtbdrugsorgpipelineclin
two
noncoval
inhibitor
also
undergo
clinic
evalu
phase
azaindol
requir
export
mycol
acid
precursor
essenti
cell
wall
biosynthesi
compound
target
enzym
probabl
clinic
sever
preclin
drugdiscoveri
programm
target
enoyl
reductas
inha
involv
biosynthesi
mycol
acid
inha
also
target
prodrug
isoniazid
nitroimidazol
pretomanid
activ
replic
nonrepl
mycobacteria
clinic
trial
like
delamanid
pretomanid
like
prodrug
number
undergo
clinic
evalu
http
wwwnewtbdrugsorgpipelineclin
sever
fluoroquinolin
investig
combin
therapi
includ
moxifloxacin
levofloxacin
wherea
antibacteri
drug
resist
technic
neglect
tropic
diseas
impact
clearli
seen
lmic
high
level
drug
resist
recent
publish
prioriti
list
prioriti
pathogen
enterobacteriacea
resist
carbapenem
third
gener
cephalosporin
acinetobact
baumannii
pseudomona
aeruginosa
carbapenemresist
new
drug
urgent
need
tackl
pathogen
drug
clinic
develop
address
addit
sever
bacteri
infect
shigellosi
typhoid
almost
exclus
affect
lmic
drug
resist
major
issu
worryingli
instanc
resist
bacteria
higher
fit
wildtyp
treatment
reliant
exist
antibacteri
least
one
billion
peopl
probabl
estim
one
helminth
nevertheless
new
antihelminth
drug
emerg
last
year
tribendimidin
show
promis
broadspectrum
activ
recent
clinic
trial
show
suitabl
altern
benzimidazol
praziquantel
variou
helminth
beyond
develop
new
treatment
focus
repurpos
drug
mostli
involv
anthelminth
approv
veterinari
use
oxantel
pamoat
licens
veterinari
drug
sinc
shown
promis
efficaci
human
clinic
trial
trichuriasi
whipworm
one
difficulttotreat
soiltransmit
combin
albendazol
pyrantel
pamoat
recent
demonstr
high
clinic
efficaci
hookworm
two
veterinari
drug
emodepsid
moxidectin
show
promis
activ
sever
human
helminth
current
undergo
clinic
trial
antimalari
compound
show
activ
schistosom
vitro
vivo
combin
test
clinic
trial
chronic
schistosoma
haematobium
infect
unfortun
advers
event
rate
high
increas
efficaci
compar
case
filari
worm
altern
strategi
target
wolbachia
endosymbiot
bacteria
result
slow
kill
worm
therebi
avoid
seriou
advers
event
exampl
four
week
treatment
doxycyclin
cure
peopl
suffer
onchocerciasi
major
aim
wolbachiadirect
therapi
find
shortercours
sever
highthroughput
phenotyp
screen
carri
discov
new
chemic
entiti
act
helminth
new
clinic
candid
report
date
fungal
infect
particularli
seriou
immunocomprom
patient
addit
common
fungal
infect
sever
found
predominantli
tropic
region
one
import
problem
mening
due
c
neoforman
estim
caus
death
per
year
among
peopl
infect
hiv
major
poorli
treat
present
need
new
efficaci
drug
mycetoma
disfigur
infect
skin
soft
tissu
particularli
neglect
diseas
endem
tropic
subtrop
area
mycetoma
caus
bacteria
actinomycetoma
fungi
eumycetoma
fungal
mycetoma
requir
long
treatment
azol
drug
resist
diseas
recurr
side
effect
common
patient
often
develop
deform
requir
amput
dndi
current
run
phase
iiiii
trial
fosravuconazol
assess
whether
azol
effect
safer
current
use
azol
itraconazol
ketoconazol
comprehens
review
current
antifung
pipelin
publish
current
treatment
use
tropic
diseas
suboptim
case
drug
avail
howev
recent
progress
drug
discoveri
human
african
trypanosomiasi
tuberculosi
malaria
show
headway
made
concert
effort
govern
chariti
foundat
productdevelop
partnership
academ
institut
pharmaceut
compani
still
long
way
go
even
diseas
area
high
attrit
rate
clinic
trial
issu
resist
mean
room
complac
multipl
new
agent
requir
diseas
area
allow
combin
therapi
progress
diseas
area
much
less
support
activ
other
